TOLLIP and COVID-19: Jin et al. [42] illustrated that SUMOylation limits the degradation of the ACE2 receptor via TOLLIP-mediated selective autophagy, thereby increasing host susceptibility to SARS-CoV-2, which could present a potential target for COVID-19 treatment.